You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
News from the melanoma sessions of the European Cancer Congress 2017
|
|---|---|
| Published in |
BMC Medicine, March 2017
|
| DOI | 10.1186/s12916-017-0826-4 |
| Pubmed ID | |
| Authors |
Piotr Rutkowski, Katarzyna Kozak |
| Abstract |
During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 16% |
| Researcher | 6 | 16% |
| Other | 5 | 14% |
| Student > Postgraduate | 4 | 11% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 19% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Nursing and Health Professions | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 10 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2017.
All research outputs
#18,538,272
of 22,959,818 outputs
Outputs from BMC Medicine
#3,225
of 3,448 outputs
Outputs of similar age
#254,153
of 333,987 outputs
Outputs of similar age from BMC Medicine
#62
of 66 outputs
Altmetric has tracked 22,959,818 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,448 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.6. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,987 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.